Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Parsa Yousefi

Showing results (11-20 of 13) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 13 results.
Medical Journal of the Islamic Republic of Iran|June 23, 2017
Congenital urogenital abnormalities in children with congenital hypothyroidismParsa Yousefi Chaijan, Fatemeh Dorreh, Mojtaba Sharafkhah, et al.
Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology|June 18, 2026
Acute and post-acute neurobehavioral responses to lysergic acid diethylamide in healthy subjects: a randomized controlled studyAbigail E Calder, Vincent J Diehl, Morten P Lietz, et al.
Frontiers in Oncology|November 4, 2024
Vδ2 T-cell engagers bivalent for Vδ2-TCR binding provide anti-tumor immunity and support robust Vγ9Vδ2 T-cell expansionLisa A King, Milon de Jong, Myrthe Veth, et al.
Pageof 2

Showing results (11-20 of 13) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 13 results.
Medical Journal of the Islamic Republic of Iran|June 23, 2017
Congenital urogenital abnormalities in children with congenital hypothyroidismParsa Yousefi Chaijan, Fatemeh Dorreh, Mojtaba Sharafkhah, et al.
Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology|June 18, 2026
Acute and post-acute neurobehavioral responses to lysergic acid diethylamide in healthy subjects: a randomized controlled studyAbigail E Calder, Vincent J Diehl, Morten P Lietz, et al.
Frontiers in Oncology|November 4, 2024
Vδ2 T-cell engagers bivalent for Vδ2-TCR binding provide anti-tumor immunity and support robust Vγ9Vδ2 T-cell expansionLisa A King, Milon de Jong, Myrthe Veth, et al.
Pageof 2